There's hope for Medicare beneficiaries who believe Medicare should negotiate with drug companies to reduce costs after members of the senate announced the recent proposed legislation, Inflation Reduction Act of 2022.
There's hope for the 86% of Medicare beneficiaries surveyed by eHealth, Inc. who believe Medicare should negotiate with drug companies to reduce costs after members of the senate announced the recent proposed legislation, Inflation Reduction Act of 2022.
The recently released survey shows that 95% of Medicare beneficiaries are worried about the impact of inflation on healthcare costs. Nearly half (45%) of the 2,500 Medicare beneficiaries surveyed say their healthcare costs have already increased due to inflation.
However, the survey was conducted before news of the possible compromise Senate bill to address the drug costs was released, so there may be light at the end of the tunnel.
"Seniors on a fixed income are particularly vulnerable to inflation's impact on health care costs," said eHealth CEO Fran Soistman, in a release. "Our survey shows the consequences of inflation are immediate and that senior citizens are concerned about their ability to afford monthly premiums and other health care costs."
According to the survey, the top two worries of Medicare beneficiaries are increased prescription drug costs and increased Medicare Part B premiums.
Although, more assistance could be around the corner as senators also agreed to extend the expiring enhanced Affordable Care Act subsidies included in the 2021 American Rescue Plan Act for three more years 2025.
Shared in another article by MHE, a one-page summary of the proposed bill says that prescription drug pricing reform will yield $288 billion in savings over 10 years, or almost 40% of the $739 billion in revenues the package is designed to produce.
Unrealistic Portrayals of Cardiac Arrest in Contemporary Film | ACC 2025
March 31st 2025Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Winrevair Reduced Risk of Morbidity and Mortality by 76% in PAH | ACC 2025
March 31st 2025In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension.
Read More
Clopidogrel Beat Aspirin in Preventing Heart Attacks After PCI | ACC 2025
March 31st 2025Clopidogrel monotherapy may be an alternative to aspirin for prevention of cardiac events in high-risk patients after percutaneous coronary intervention, according to a new study presented at ACC 2025.
Read More